Alcon is to buy ESBATech, a private Swiss biotechnology company focused on antibody fragments, for up to $589 million.
The agreement gives Alcon a range of biologics that have potential in eye care, expanding its research capabilities outside small...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?